Notizie AIOM – anno XVII
Antoni Ribas, MD, PhD, Elected AACR President-Elect
March 28, 2019 - The members of the American Association for Cancer Research (AACR) have elected Antoni Ribas, MD, PhD, as their President-Elect for 2019–2020. He will officially become President-Elect at the AACR Annual Meeting 2019 and he will assume the presidency ...Leggi tutto
FDA Approval Sought for Frontline Daratumumab Regimen in Transplant-Eligible Myeloma
March 26, 2019 - A supplemental biologics license application (sBLA) has been submitted to the FDA for daratumumab in combination with bortezomib, thalidomide, and dexamethasone (VTd) for the treatment of patients with newly diagnosed multiple myeloma who are eligible for ...Leggi tutto
FDA advances landmark policy changes to modernize mammography services and improve their quality
March 27, 2019 - Today, the U.S. Food and Drug Administration announced important new steps to modernize breast cancer screening and help empower patients with more information when they are considering important decisions regarding their breast health care. For the first ...Leggi tutto
Statement from FDA Commissioner Scott Gottlieb, M.D., on new steps to strengthen agency’s safety requirements aimed at mitigating risks associated with transmucosal immediate-release fentanyl products
March 27, 2019 - As the FDA continues to forcefully confront the opioid crisis, rationalizing prescribing practices and ensuring safe and appropriate use of these powerful medications remains a cornerstone of our efforts. More appropriate prescribing can reduce the rate ...Leggi tutto
FDA Grants Breakthrough Designation to Ivosidenib Combo for Newly Diagnosed IDH1+ AML
March 27, 2019 - The FDA has granted a breakthrough therapy designation to the combination of ivosidenib and azacitidine for the treatment of newly diagnosed patients with IDH1-mutant acute myeloid leukemia (AML) ≥75 years old or are ineligible for intensive induction ...Leggi tutto
EU Approval Sought for Frontline Daratumumab/Rd in Transplant-Ineligible Myeloma
March 22, 2019 - A Type II variation application has been submitted to the European Medicines Agency for the combination of daratumumab with lenalidomide and dexamethasone (DRd) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous ...Leggi tutto